
Thrombosis Research 129 (2012) 245–249

Contents lists available at SciVerse ScienceDirect

Thrombosis Research

journal homepage: www.elsevier.com/locate/thromres

Review Article

Blood platelet biochemistry ✩

Kathleen Broos, Simon F. De Meyer, Hendrik B. Feys, Karen Vanhoorelbeke, Hans Deckmyn ✩

Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven campus Kortrijk, Kortrijk, Belgium

ARTICLE INFO

Article history:

Received 22 September 2011

Received in revised form 27 October 2011

Accepted 2 November 2011

Available online 26 November 2011

Keywords:

Platelet adhesion

activation

signal transduction

secretion

aggregation

ABSTRACT

Defects in platelet function or formation increase the risk for bleeding or thrombosis, which indicates the crucial role for platelets in maintaining haemostasis in normal life. Upon vascular injury, platelets instantly adhere to the exposed extracellular matrix which results in platelet activation and aggregation and the formation a haemostatic plug that stops bleeding. To prevent excessive platelet aggregate formation that eventually would occlude the vessels, this self-amplifying process nevertheless requires a tight control. This review intends to give a comprehensive overview of the currently established main mechanisms in platelet function.

© 2011 Elsevier Ltd. All rights reserved.

Contents

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
collagen, von Willebrand factor (VWF), laminin, fibronectin and thrombospondin. Since fibrillar collagens type I and III are very effective platelet activators and have a high affinity for VWF, they are considered to be the most thrombogenic matrix-mediators of platelet adhesion. [2]

Depending on the rheological conditions, platelet adhesion occurs via different mechanisms. Especially at high shear rates, VWF is essential to decelerate fast-flowing platelets by reversible binding of its A1 domain with platelet glycoprotein (GP) Ibα. This initial platelet tethering allows the establishment of additional interactions between platelets and the subendothelial matrix, e.g. engagement of the collagen receptors GPVI and α2β1. This eventually leads to definitive platelet arrest and subsequent platelet thrombus formation. Optimal platelet adhesion relies on synergistic actions between the different platelet receptors. For example, both collagen receptors reinforce each other's activity [3], but also α2β1 and GPIbα cooperate synergistically, further reinforced by activation via GPVI [4,5].

**GPIba–VWF**

VWF is a large, multimeric glycoprotein that is present in plasma, the subendothelial matrix and storage granules in both platelets (α-granules) and endothelial cells (Weibel-Palade bodies). [6] Upon injury of the vessel wall, circulating VWF rapidly binds to exposed collagen through collagen binding sites that are present in the VWF A1 and, more importantly, VWF A3 domain [7,8]. Self-association between circulating VWF multimers and matrix-bound [9], platelet-bound [10] or endogenous subendothelial VWF is also possible and involves multiple domain interactions [11].

After immobilization, VWF undergoes conformational changes that expose the binding site in its A1 domain for GPIbα [12–14]. GPIbα, the only receptor on a non-activated platelet with a significant affinity for VWF, is part of the GPIb/IX/V complex, which consists of the leucine-rich repeat glycoproteins GPIbα (130 kDa), GPIbβ (25 kDa), GPIX (22 kDa) and GPV (88 kDa) [15] in a 2:4:2:1 stoichiometry.

The transient interactions between VWF and GPIbα allows ‘rolling’ of platelets on sites of vascular injury, keeping them in close contact with the exposed subendothelial matrix. As a result, other platelet receptors, such as those for collagen, are engaged, which leads to eventual platelet activation and firm platelet adhesion via high affinity β1 and β3 integrins. Activated platelets are then cross-linked by binding of VWF to GPIbα under high shear and of VWF and fibrinogen to the integrin αIIbβ3 once activated. Patients with deficiencies in either VWF (von Willebrand disease [6]) or GPIbα (Bernard-Soulier Syndrome [16]) suffer from severe bleeding symptoms, underlining the key role of the VWF-GPIbα interaction in normal haemostasis.

GPIbα has multiple binding partners, including α-thrombin (FIIa) [17] which engages the receptor through a two-site mechanism recently described [18]. Despite improved molecular insights, it remains unclear what major anti- or prothrombotic effect this interaction has both on α-thrombin and GPIbα. Nevertheless, in experimental thrombosis models, it is clear that thrombosis is much more impaired in mice lacking the extracellular part of GPIbα than in mice lacking VWF [19]. This suggests that besides VWF, also the other GPIbα ligands (e.g. thrombospondin-1) can mediate thrombus formation.

**Platelet collagen receptors GPVI and α2β1**

GPVI (62 kDa) is a platelet-specific member of the immunoglobulin superfamily, consisting of two extracellular immunoglobulin-like domains, a mucin-like stalk, a transmembrane region and a short cytoplasmic tail [20]. In the platelet membrane, GPVI is associated with the FcRγ-chain, which bears immunoreceptor tyrosine-based activation motifs (ITAM) for signal transduction [21]. The role of GPVI is considered to be eliciting strong signaling rather than establishing stable platelet adhesion [5]. Indeed, GPVI has only a low affinity for collagen (involving the recognition of triplets consisting of Gly, Pro and Hyp [22–24]) whereas GPVI/FcRγ-chain-mediated signaling is crucial for platelet adhesion on collagen [25].

α2β1 (GPIa/IIa, VLA-2 or CD49b/CD29) is an I-domain containing integrin with a high affinity for the Gly-Phe-Hyp-Glu-Arg sequence in collagen [26]. Efficient collagen binding depends on activation of α2β1, which shifts the conformation of this integrin from a low-affinity to a high-affinity state. An intermediate state of α2β1 has also been reported [27–29]. The precise signaling pathway leading to α2β1 activation is not yet entirely elucidated but involvement of GPVI and/or prior activation of αIIbβ3 have been suggested [30–32].

**Platelet activation (Fig. 1)**

A major signal transduction pathway by which platelets are activated involves a cascade of tyrosine kinases, as occurs when GPIb is occupied by VWF [33], the FcRγII receptor by antibody complexes, the receptors Tyro3, Axl and Mer by GAS6 [34], GPVI-FcRγ by collagen [35] or CLEC2 by podoplanin, the latter essential for the separation of the lymphatic system from the blood vessels in embryonic development [36].

When GPVI is crosslinked and clustered by collagen (or a collagen-related peptide, the snake C type lectin convulxin, or antibodies) [20] this leads to activation of the Src tyrosine kinases Fyn and Lyn, bound to the cytoplasmatic tail of GPVI. The ITAMs present on the FcRγ-chain are phosphorylated by Fyn and Lyn, next allowing the recruitment of the tyrosine kinase Syk. Syk in turn induces a signaling cascade finally resulting in the Tyr-phosphorylation and activation of phospholipase Cγ2 (PLCγ2), for which in addition both the adaptor protein SLP-76 and “linker for activation of T cell” (LAT) are required [35].

Activated PLCγ2 hydrolyzes phosphatidylinositol 4,5-bisphosphate to produce inositol 1,4,5 trisphosphate (IP₃) and membrane bound 1,2-diacylglycerol (DAG). IP₃ rapidly diffuses and binds to its receptor IP₃R, a calcium-selective channel on the platelet dense tubular system (DTS), through which now an efflux of Ca²⁺ from the DTS starts with increasing Ca²⁺ levels in the cytoplasm.

Stromal interaction molecule 1 (STIM1) equally is a DTS transmembrane protein, which contains a Ca²⁺ binding EF hand motif in its DTS region, which in resting platelets, is occupied by Ca²⁺. However when Ca²⁺ levels within the DTS are reduced following IP₃R activation, STIM1 is no longer occupied by Ca²⁺ and translocates to the plasma membrane where it associates with and opens the store-operated calcium channel Orai1, allowing influx of plasma Ca²⁺ entry in activated platelets with an even further increase in cytosolic calcium [37,38].

The hydrophobic DAG in the membrane together with Ca²⁺, bound to phosphatidylserine, induces the translocation of the serine/threonine protein kinase C (PKC) to the membrane, by which it becomes activated to play a prominent role in the secretion reaction.

Raising cytosolic Ca²⁺ and DAG concentrations within the adherent platelet cytosol results in a plethora of reactions including phospholipase A2 (PLA2) activation, platelet shape change, granule secretion and finally aggregation. The Ca²⁺-increase is counterbalanced by plasma membrane Ca²⁺ATPases (PMCA) that extrude cytosolic Ca²⁺ towards the extracellular medium and sarcoplasmic reticulum ATPases (SERCA) that pump Ca²⁺ into the DTS [39].

Increased cytosolic Ca²⁺ levels also is responsible for the exposure of negatively charged phosphatidylserine at the platelet surface [40] due to activation of a scramblase, recently identified as the transmembrane protein 16 F (TMEM16F) [41]. This negatively charged procoagulant surface provides together with bound Ca²⁺, binding sites for especially the vitamin K-dependent clotting factors, co-factors and their substrates, which accelerate the coagulation cascade. In addition, during this process also procoagulant microparticles are formed [42]. The importance of the contribution of the procoagulant surface is

K. Broos et al. / Thrombosis Research 129 (2012) 245–249

![Diagram](attachment:diagram.png)

Fig. 1. Schematic overview of the main platelet receptors and effectors involved in platelet activation, amplification, aggregation and inhibition.

reflected in the bleeding phenotype of Scott Syndrome due to a defect in membrane reshuffling, and indeed a patient was identified in which a mutation at a splice-acceptor site of the gene encoding TMEM16F, causing premature termination of the protein, was found [40].

The main inducer of coagulation, thrombin, in addition also is a potent platelet stimulator. Thrombin however, unlike all the other ligands involved in platelet activation, activates its receptors, the Protease Activated Receptors (PAR) 1 and 4 in man, by cleaving an N-terminal part at a consensus site. The newly generated N-terminus now serves as a tethered ligand that induces receptor activation [43].

### Amplification of the signal transduction

Following initial platelet activation, a number of amplification mechanisms are operating that result in additional platelet recruitment: thromboxane A2 is generated and the content of platelet granules is released. Platelet α-granules contain chemokines, (anti-) angiogenic molecules, growth factors and both anti- and pro-thrombotic molecules, amongst which also VWF and fibrinogen [44]. Mass spectrometry analysis has indicated that over 280 different proteins might be present [45]. Dense granules on the other hand contain fewer proteins, but Ca²⁺ ions and products such as ADP, ATP, histamine and serotonin. Lysosomes finally mainly secrete serine peptidases, carbohydrates and phosphatases [46].

Thromboxane A2 (TXA₂) is produced as a consequence of increased Ca²⁺-levels that are necessary for the activation of PLA2 by phosphorylation by P38-mitogen-activated protein kinase (MAPK) [47]. PLA2 cleaves fatty acids from the sn-2 position in phospholipids, with e.g. the release of arachidonic acid (or 5,8,11,14 eicosatetraenoic acid), itself a substrate for cyclo-oxygenase (in platelets COX-1), with prostaglandin endoperoxides PGG₂ and PGH₂ as first products. These are next transformed by thromboxane synthase into the potent, but short-lived TXA₂. Released TXA₂ induces smooth muscle cell contraction but also activates additional platelets by acting on its TP receptor.

The TP receptor is a G-protein coupled receptor (GPCR) that interacts with Gq that has PLCβ2 as main effector molecule. Also the thrombin receptors PAR-1 and PAR-4, the ADP receptor P2Y₁, PAF-1-receptor for PAFacether, the V-1 receptor for vasopressin and the serotonin (5-hydroxytryptamine) receptor 5HT2A, couple via Gq to PLCβ2. PLCβ2 activation, like PLCγ2, further increases cytosolic Ca²⁺ levels [48]. TP and PAR-receptors in addition are coupled to G13 that activates Rho guanine nucleotide exchange factors, which start the Rho/Rho-kinase-mediated pathway finally resulting in the phosphorylation of myosin light chain (MLC). Stimulation of Rho/Rho-kinase and MLC phosphorylation increases actomyosin contractility and regulation of microtubule coils allowing changes in the platelet shape [49,50].

ADP is released from platelet dense granules and provides a second feedback amplification signal by binding to the P2Y₁-receptor equally coupled to Gq. However it also binds to P2Y₁₂, that itself is coupled to Goi2, that inhibits adenylyl cyclase and hence prevents increases in cAMP generation. Gi, in platelets, also is coupled to a.o. the thrombin receptors PAR-1 and — 4 and the adrenaline receptor α2A [51]. Gi furthermore also stimulates phosphoinositide 3-kinase β (PI3Kβ) that produces phosphatidylinositol-3,4,5-trisphosphate, interacting with a variety of downstream effectors such as the serine/threonine kinase Akt/protein kinase B (PKB), extracellular signal-regulated kinase 2 (ERK2), Rap1B, Rac and ultimately more Ca²⁺ mobilization [52].

### Platelet aggregation as a result of inside-out activation

After platelet adhesion and activation, the symmetric molecule fibrinogen crosslinks different platelets by binding to the activated

integrin αIIbβ3 resulting in platelet aggregation. Absence of platelet aggregation due to αIIbβ3 deficiencies results in the severe bleeding disorder Glanzmann's Thrombasthenia demonstrating the prime and non-redundant role of αIIbβ3 in platelet aggregation.

On resting platelets however, αIIbβ3 has a low affinity for fibrinogen and VWF. This low affinity conformation is stabilized by a salt bridge in the membrane proximal cytosolic regions between Asp723 of β3 integrin and Arg995 of αIIb integrin and by the hydrophobic residues immediately N-terminal to the arginine and aspartate residues [53].

In activated platelets, increased Ca²⁺ levels lead to the activation of “Ca²⁺ and diacylglycerol regulated guanine nucleotide exchange factor I” (CalDAG-GEFI) [54,55], which itself activates Rap1b, a small GTP binding protein. The interaction of activated Rap1b with Rap1-interacting adaptor molecule (RIAM) [56] and talin results in the formation of an ‘activation complex’. The interaction of talin with activated Rap1 and RIAM occurs through its phosphotyrosine binding domain (PTB) and through a rather unique second interaction site required for integrin activation [57] leading to the unmasking of the integrin-binding site on talin [58]. Talin hence binds to the integrin β3 tail which leads to the disruption of the clasp between the α and β subunits [59]. This separation of the membrane proximal cytosolic regions of αIIbβ3 is transmitted to the extracellular domains which change from a bent into an extended conformation. In this way, the integrin binding site on αIIbβ3 is exposed and activated: αIIbβ3 now can bind fibrinogen and VWF [60].

Recently, also kindlin3 [61,62] has been shown to be an important mediator of integrin activation, as both mice and patients with dysfunctional kindlin3 have defective integrin activation. However, the interplay between talin and kindlin3 in integrin activation has not been elucidated yet.

### Signals that limit platelet activation and aggregation

Platelet clumping should be limited to the sites of vessel damage. Nitric oxide (NO) and prostacyclin (PGI₂) and the prostaglandin PGD₂ provide strong inhibitory signals that prevent platelets from undesired activation and restrict thrombus size.

Whereas in platelets TxA₂ is produced by COX-1 and thromboxane synthase, in endothelial cells mainly PGI₂ is synthesized by action of COX-2 [63] and prostacyclin synthase. PGI₂ acts on its platelet receptor IP, a GPCR that couples to Gs, a stimulator of membrane bound adenyllyl cyclase. This results in increased levels of cAMP which then bind and activate the cAMP-dependent protein kinase A (PKA) [64] that on its turn phosphorylates many regulatory proteins like vasodilator-stimulated phosphoprotein (VASP). Phosphorylation of VASP on the hand hampers the actin-filament mediated cytoskeleton reorganization accompanied with platelet aggregation and spreading [65,66] and on the other hand, as VASP is also linked to focal adhesions, the inside-out activation of co-localized integrin αIIbβ3 molecules necessary for fibrinogen binding during aggregation [67]. PKA furthermore directly phosphorylates the IP3-receptor and the plasma membrane Ca²⁺ ATPase (PMCA)s4b, thereby suppressing Ca²⁺ release from the DTS [68] and stimulating the active transport of cytosolic Ca²⁺ to the extracellular environment [39], respectively.

NO is produced from L-arginine by nitric oxide-synthases (NOS) of which 3 isoforms exist: the endothelial NOS (eNOS/NOS3), the inducible NOS (iNOS/NOS2), and the neuronal NOS (nNOS/NOS1) [69]. The contribution of the different NOS species in negatively regulating platelet responses is poorly understood due to a multitude of conflicting data.

Endothelial derived NO diffuses through the platelet membrane where it binds to soluble guanylyl cyclase (sGC). Increased sGC activity leads to an elevation of the intracellular cGMP level with concomitant stimulation of the PKG activity. This gives rise to a higher phosphorylation status of several proteins [70–72,66] which subsequently inhibit

intracellular Ca²⁺ rises, cytoskeletal rearrangements, integrin activation and dense granule secretion [73–75].

In addition, endothelial cells are the only cell type that express the apyrase CD39/NTPDase and the 5'nucleotidase CD73 together on their cell surface, enabling them to convert platelet released ATP and ADP, thus reducing its proaggregatory effects, to adenosine which through its binding to the platelet A2A receptor in its turn enhances platelet cAMP levels [76].

### Perspectives

Our current knowledge on the platelet biochemistry is the compilation of meticulous work by many dedicated researchers over many years. We however are already witnessing a knowledge acceleration with the different “omics” approaches that also are being applied to platelets including studies on proteomics with a.o. so called secretome and sheddome studies, comparative platelet transcription or platelet expression profiles etc. All of which are identifying novel platelet proteins at high speed. Functional genomics studies will now allow to assign a role for these newly discovered proteins in platelet signaling ad physiology thereby completing our current understanding of platelet function.

### Conflict of interest

The authors state no conflict of interest.

### Acknowledgments

SFD is and HBF was a fellow of the Research Foundation Flanders (Fonds voor Wetenschappelijk Onderzoek, Vlaanderen FWO). This work was supported by a KU Leuven Campus Impulse Financing (CIF/07/02) and Concerted Research Action (GOA09/013) grant.

### References

[1] Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science 2010;328: 562–4.

[2] Farndale RW, Siljander PR, Onley DJ, Sundaresan P, Knight CG, Barnes MJ. Collagen-platelet interactions: recognition and signalling. Biochem Soc Symp 2003: 81–94.

[3] Chen H, Kahn ML. Reciprocal signaling by integrin and nonintegrin receptors during collagen activation of platelets. Mol Cell Biol 2003;23:4764–77.

[4] Siljander PRM, MunniX ICA, Smethurst PA, Deckmyn H, Lindhout T, Ouwehand WH, et al. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 2004;103:1333–41.

[5] Pugh N, Simpson AM, Smethurst PA, de Groot PG, Raynal N, Farndale RW. Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. Blood 2010;115:5069–79.

[6] De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009;113:5049–57.

[7] Lankhof H, van Hoeij M, Schiphorst ME, Bracke M, Wu YP, IJsseldijk MJ, et al. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost 1996;75:950–8.

[8] Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermeylen J. von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem J 1997;324(Pt. 1):185–91.

[9] Savage B, Sixma JJ, Ruggeri ZM. Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci U S A 2002;99:425–30.

[10] Dayananda KM, Singh I, Mondal N, Neelamegham S. von Willebrand factor self-association on platelet Gplb{alpha} under hydrodynamic shear: effect on shear-induced platelet activation. Blood 2010;116:3990–8.

[11] Ulrichts H, Vanhoorelbeke K, Girma JP, Lenting PJ, Vauterin S, Deckmyn H. The von Willebrand factor self-association is modulated by a multiple domain interaction. J Thromb Haemost 2005;3:552–61.

[12] Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost 2007;5:1363–70.

[13] Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A 2004;101:10578–83.

[14] Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, Vanhoorelbeke K, et al. Shielding of the A1 Domain by the D'D3 Domains of von Willebrand Factor Modulates Its Interaction with Platelet Glycoprotein Ib-IX-V. J Biol Chem 2006;281: 4699–707.

[15] Andrews RK, Gardiner EE, Shen Y, Whisstock JC, Berndt MC. Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 2003;35:1170–4.
[16] Salles II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Inherited traits affecting platelet function. Blood Rev 2008;22:155–72.
[17] Ruggeri ZM, Zarpellon A, Roberts JR, Mc Clintock RA, Jing H, Mendolicchio GL. Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib. Thromb Haemost 2010;104:894–902.
[18] Zarpellon A, Celikel R, Roberts JR, McClintock RA, Mendolicchio GL, Moore KL, et al. Binding of alpha-thrombin to surface-anchored platelet glycoprotein Ib(alpha) sulfotyrosines through a two-site mechanism involving exosite I. Proc Natl Acad Sci U S A 2011;108:8628–33.
[19] Bergmeier W, Piffath CL, Goerge T, Cifuni SM, Ruggeri ZM, Ware J, et al. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A 2006;103:16900–5.
[20] Jung SM, Moroi M. Platelet glycoprotein VI. Adv Exp Med Biol 2008;640:53–63.
[21] Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res 2004;114:221–33.
[22] Knight CG, Morton LF, Onley DJ, Peachey AR, Ichinohe T, Okuma M, et al. Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen. Cardiovasc Res 1999;41:450–7.
[23] Jarvis GE, Raynal N, Langford JP, Onley DJ, Andrews A, Smethurst PA, et al. Identification of a major GpVI-binding locus in human type III collagen. Blood 2008;111:4986–96.
[24] Smethurst PA, Onley DJ, Jarvis GE, O'Connor MN, Knight CG, Herr AB, et al. Structural basis for the platelet-collagen interaction: the smallest motif within collagen that recognizes and activates platelet Glycoprotein VI contains two glycine-proline-hydroxyproline triplets. J Biol Chem 2007;282:1296–304.
[25] Schulz C, Leuschen NV, Frohlich T, Lorenz M, Pfeiler S, Gleissner CA, et al. Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation. Blood 2010;115:4102–10.
[26] Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin alpha2beta1. Cell 2000;101:47–56.
[27] Van de Walle GR, Vanhoorelbeke K, Majer Z, Illyes E, Baert J, Pareyn I, et al. Two functional active conformations of the integrin {alpha}2{beta}1, depending on activation condition and cell type. J Biol Chem 2005;280:36873–82.
[28] Jung SM, Moroi M. Platelet collagen receptor integrin alpha2beta1 activation involves differential participation of ADP-receptor subtypes P2Y1 and P2Y12 but not intracellular calcium change. Eur J Biochem 2001;268:3513–22.
[29] Jung SM, Moroi M. Signal-transducing mechanisms involved in activation of the platelet collagen receptor integrin alpha(2)beta(1). J Biol Chem 2000;275:8016–26.
[30] Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, et al. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res 2006;118:371–80.
[31] Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad R, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 2001;20:2120–30.
[32] Van de Walle GR, Schoolmeester A, Iserbyt BF, Cosemans JM, Heemskerk JW, Hoylaerts MF, et al. Activation of alphallbbeta3 is a sufficient but also an imperative prerequisite for activation of alpha2beta1 on platelets. Blood 2007;109:595–602.
[33] Du X. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. Curr Opin Hematol 2007;14:262–9.
[34] Cosemans JM, Van KR, Olieslagers S, Schurgers LJ, Verheyen FK, Munnix IC, et al. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization. J Thromb Haemost 2010;8:1797–808.
[35] Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost 2010;8:1456–67.
[36] Cueni IN, Chen L, Zhang H, Marino D, Huggenberger R, Alitalo A, et al. Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin. Blood 2010;116:4376–84.
[37] Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. J Thromb Haemost 2009;7:1057–66.
[38] Bergmeier W, Stefanini L. Novel molecules in calcium signaling in platelets. J Thromb Haemost 2009;7(Suppl. 1):187–90.
[39] Bobe R, Bredoux R, Corvazier E, Lacabaratz-Porret C, Martin V, Kovacs T, et al. How many Ca(2+)-ATPase isoforms are expressed in a cell type? A growing family of membrane proteins illustrated by studies in platelets. Platelets 2005;16:133–50.
[40] Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thromb Res 2010;125(Suppl. 1):S46–8.
[41] Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010;468:834–8.
[42] Morel O, Morel N, Freyssinet JM, Toti F. Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses. Platelets 2008;19:9–23.
[43] Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057–68.
[44] Reed GL. Platelet secretory mechanisms. Semin Thromb Hemost 2004;30:441–50.
[45] Maynard DM, Heijnen HF, Horne MK, White JG, Gahl WA. Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost 2007;5:1945–55.

[46] McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 1999;95:1–18.
[47] Kramer RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ, et al. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 1996;271:27723–9.
[48] Brass LF, Manning DR, Cichowski K, Abrams CS. Signaling through G proteins in platelets: to the integrins and beyond. Thromb Haemost 1997;78:581–9.
[49] Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006;99:1293–304.
[50] Getz TM, Dangelmaier CA, Jin J, Daniel JL, Kunapuli SP. Differential phosphorylation of myosin light chain (Thr)18 and (Ser)19 and functional implications in platelets. J Thromb Haemost 2010;8:2283–93.
[51] Cattaneo M. The platelet P2 receptors; 2006. p. 201–20.
[52] Garcia A, Kim S, Bhavaraju K, Schoenwaelder SM, Kunapuli SP. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J 2010;429:369–77.
[53] Vinogradova O, Velyvis A, Velyviene A, Hu B, Haas TA, Plow EF, et al. A structural mechanism of integrin alpha(IIb)beta(3) "inside-out" activation as regulated by its cytoplasmic face. Cell 2002;110:587–97.
[54] Bergmeier W, Goerge T, Wang HW, Crittenden JR, Baldwin AC, Cifuni SM, et al. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Invest 2007;117:1699–707.
[55] Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004;10:982–6.
[56] Han J, Lim CJ, Watanabe N, Soriani A, Ratnikov B, Calderwood DA, et al. Reconstructing and deconstructing agonist-induced activation of integrin alphallb-beta3. Curr Biol 2006;16:1796–806.
[57] Rodius S, Chaloin O, Moes M, Schaffner-Reckinger E, Landrieu I, Lippens G, et al. The talin rod IBS2 alpha-helix interacts with the beta3 integrin cytoplasmic tail membrane-proximal helix by establishing charge complementary salt bridges. J Biol Chem 2008;283:24212–23.
[58] Banno A, Ginsberg MH. Integrin activation. Biochem Soc Trans 2008;36:229–34.
[59] Anthis NJ, Wegener KL, Ye F, Kim C, Goult BT, Lowe ED, et al. The structure of an integrin/talin complex reveals the basis of inside-out signal transduction. EMBO J 2009;28:3623–32.
[60] Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010;11:288–300.
[61] Malinin NL, Zhang L, Choi J, Ciocea A, Razorenova O, Ma YQ, et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med 2009;15:313–8.
[62] Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008;14:325–30.
[63] Ruan CH, So SP, Ruan KH. Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: Mechanisms of COX-2 inhibitor risk to heart disease. Life Sci 2011;88:24–30.
[64] Rex S, Freedman NJ. Inhibition of platelet function by the endothelium. Second edition; 2006. p. 251–79.
[65] Harbeck B, Huttelmaier S, Schluter K, Jockusch BM, Illenberger S. Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem 2000;275:30817–25.
[66] Reinhard M, Jarchau T, Walter U. Actin-based motility: stop and go with Ena/VASP proteins. Trends Biochem Sci 2001;26:243–9.
[67] Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999;18:37–48.
[68] Cavallini L, Coassin M, Borean A, Alexandre A. Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem 1996;271:5545–51.
[69] Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593–615.
[70] Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990;87:5193–7.
[71] Chung AW, Jurasz P, Hollenberg MD, Radomski MW. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol 2002;135:1123–32.
[72] Antl M, von Bruhl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, et al. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood 2007;109:552–9.
[73] Walter U, Gambaryan S. cGMP and cGMP-dependent protein kinase in platelets and blood cells. Handb Exp Pharmacol 2009:533–48.
[74] Roberts W, Riba R, Homer-Vanniasinkam S, Farndale RW, Naseem KM. Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. J Thromb Haemost 2008;6:2175–85.
[75] Roberts W, Michno A, Aburima A, Naseem KM. Nitric oxide inhibits von Willebrand factor-mediated platelet adhesion and spreading through regulation of integrin alpha(IIb)beta(3) and myosin light chain. J Thromb Haemost 2009;7:2106–15.
[76] Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, et al. Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost 2003;1:2497–509.
